JP2004518723A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004518723A5 JP2004518723A5 JP2002564504A JP2002564504A JP2004518723A5 JP 2004518723 A5 JP2004518723 A5 JP 2004518723A5 JP 2002564504 A JP2002564504 A JP 2002564504A JP 2002564504 A JP2002564504 A JP 2002564504A JP 2004518723 A5 JP2004518723 A5 JP 2004518723A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrimidine
- alkyl
- pharmaceutically acceptable
- dicarboxylic acid
- benzylamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- XIEOKRXVAACBHI-UHFFFAOYSA-N pyrimidine-4,6-dicarboxylic acid Chemical compound OC(=O)C1=CC(C(O)=O)=NC=N1 XIEOKRXVAACBHI-UHFFFAOYSA-N 0.000 claims 17
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 16
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 16
- 125000005843 halogen group Chemical group 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- QCTBMLYLENLHLA-UHFFFAOYSA-N aminomethylbenzoic acid Chemical compound NCC1=CC=C(C(O)=O)C=C1 QCTBMLYLENLHLA-UHFFFAOYSA-N 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- -1 1,3-benzodioxol-5-ylmethyl Chemical group 0.000 claims 5
- GRRIMVWABNHKBX-UHFFFAOYSA-N (3-methoxyphenyl)methanamine Chemical compound COC1=CC=CC(CN)=C1 GRRIMVWABNHKBX-UHFFFAOYSA-N 0.000 claims 4
- 102100027995 Collagenase 3 Human genes 0.000 claims 4
- 108050005238 Collagenase 3 Proteins 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 claims 3
- URBXYCAJWJKVEC-UHFFFAOYSA-N 2,1,3-benzothiadiazol-5-ylmethanamine Chemical compound C1=C(CN)C=CC2=NSN=C21 URBXYCAJWJKVEC-UHFFFAOYSA-N 0.000 claims 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 3
- 229940125532 enzyme inhibitor Drugs 0.000 claims 3
- 239000002532 enzyme inhibitor Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- YMVFJGSXZNNUDW-UHFFFAOYSA-N (4-chlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1 YMVFJGSXZNNUDW-UHFFFAOYSA-N 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- AQBJGAUQEJFPKZ-UHFFFAOYSA-N methyl 4-(aminomethyl)benzoate Chemical compound COC(=O)C1=CC=C(CN)C=C1 AQBJGAUQEJFPKZ-UHFFFAOYSA-N 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- SJBQXDAJQLKGKC-UHFFFAOYSA-N 2,1,3-benzoxadiazol-5-ylmethanamine Chemical compound C1=C(CN)C=CC2=NON=C21 SJBQXDAJQLKGKC-UHFFFAOYSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- WSCXXRULRVJTPG-UHFFFAOYSA-N bis(1,3-benzodioxol-5-ylmethyl) pyrimidine-4,6-dicarboxylate Chemical compound C1=C2OCOC2=CC(COC(=O)C=2C=C(N=CN=2)C(OCC=2C=C3OCOC3=CC=2)=O)=C1 WSCXXRULRVJTPG-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- HDOUGSFASVGDCS-UHFFFAOYSA-N pyridin-3-ylmethanamine Chemical compound NCC1=CC=CN=C1 HDOUGSFASVGDCS-UHFFFAOYSA-N 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26877901P | 2001-02-14 | 2001-02-14 | |
| PCT/IB2002/000190 WO2002064571A1 (en) | 2001-02-14 | 2002-01-18 | Pyrimidine matrix metalloproteinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004518723A JP2004518723A (ja) | 2004-06-24 |
| JP2004518723A5 true JP2004518723A5 (enExample) | 2005-07-28 |
Family
ID=23024438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002564504A Pending JP2004518723A (ja) | 2001-02-14 | 2002-01-18 | ピリミジンマトリックスメタロプロテイナーゼ阻害剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6936616B2 (enExample) |
| EP (1) | EP1368323B1 (enExample) |
| JP (1) | JP2004518723A (enExample) |
| AT (1) | ATE472535T1 (enExample) |
| BR (1) | BR0207209A (enExample) |
| CA (1) | CA2433772C (enExample) |
| DE (1) | DE60236851D1 (enExample) |
| DO (1) | DOP2002000328A (enExample) |
| GT (1) | GT200200010A (enExample) |
| MX (1) | MXPA03004920A (enExample) |
| PA (1) | PA8538401A1 (enExample) |
| PE (1) | PE20020874A1 (enExample) |
| TN (1) | TNSN02010A1 (enExample) |
| UY (1) | UY27154A1 (enExample) |
| WO (1) | WO2002064571A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2002000328A (es) | 2001-02-14 | 2003-08-30 | Warner Lambert Co | Pirimidinas inhibidoras de metaloproteinasas de matriz |
| DOP2002000332A (es) | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Inhibidores de piridina de metaloproteinasas de la matriz |
| DOP2002000333A (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz |
| US6924276B2 (en) | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
| US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
| CA2462442A1 (en) | 2001-10-12 | 2003-04-24 | Warner-Lambert Company Llc | Alkyne matrix metalloproteinase inhibitors |
| US6933298B2 (en) | 2001-12-08 | 2005-08-23 | Aventis Pharma Deutschland Gmbh | Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases |
| DE10160357A1 (de) * | 2001-12-08 | 2003-06-18 | Aventis Pharma Gmbh | Verwendung von Pyridin-2,4-dicarbonsäurediamiden und Pyrimidin-4,6-dicarbonsäurediamiden zur selektiven Inhibierung von Kollagenasen |
| US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| US6747147B2 (en) | 2002-03-08 | 2004-06-08 | Warner-Lambert Company | Oxo-azabicyclic compounds |
| US20040006077A1 (en) * | 2002-06-25 | 2004-01-08 | Bernard Gaudilliere | Thiazine and oxazine derivatives as MMP-13 inhibitors |
| EP1536786A1 (en) * | 2002-07-17 | 2005-06-08 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
| AU2003281169A1 (en) * | 2002-07-17 | 2004-02-02 | Warner-Lambert Company Llc | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
| CA2492391A1 (en) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
| MXPA05000476A (es) * | 2002-07-17 | 2005-03-23 | Warner Lambert Co | Combinacion de un inhibidor alquino alosterico de metaloproteinasa-13 de matriz con celecoxib o valdecoxib. |
| EP1539709A1 (en) | 2002-08-13 | 2005-06-15 | Warner-Lambert Company LLC | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
| WO2004014384A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
| AU2003250475A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors |
| WO2004014892A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Monocyclic derivatives as matrix metalloproteinase inhibitors |
| PA8578101A1 (es) | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
| AU2003250482A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Phthalimide derivatives as matrix metalloproteinase inhibitors |
| AU2003253150A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Chromone derivatives as matrix metalloproteinase inhibitors |
| WO2004014908A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Heterobicylcic metalloproteinase inhibitors |
| AU2003253165A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| AU2003250470A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidinone fused bicyclic metalloproteinase inhibitors |
| MXPA05001784A (es) * | 2002-08-13 | 2005-04-25 | Warner Lambert Co | Derivados de isoquinolina como inhibidores de metaloproteinasa de matriz. |
| WO2004014909A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
| BR0313385A (pt) | 2002-08-13 | 2005-06-14 | Warner Lambert Co | Derivados de pirimidina-2,4-diona como inibidores de metaloproteinase da matriz |
| AU2003250466A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
| AU2003249540A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
| WO2004014354A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
| RU2344129C2 (ru) | 2002-11-02 | 2009-01-20 | Санофи-Авентис Дойчланд Гмбх | Новые диамиды пиримидин-4,6-дикарбоновой кислоты для селективного ингибирования коллагеназ |
| US7166609B2 (en) | 2002-11-02 | 2007-01-23 | Sanofi-Aventis Deutschland Gmbh | Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases |
| DE10251019A1 (de) * | 2002-11-02 | 2004-05-19 | Aventis Pharma Deutschland Gmbh | Neue Pyrimidin-4,6-dicarbonsäurediamide zur selektiven Inhibierung von Kollagenasen |
| DE10300017A1 (de) * | 2003-01-03 | 2004-07-15 | Aventis Pharma Deutschland Gmbh | Selektive MMP 13 Inhibitoren |
| US20040142950A1 (en) * | 2003-01-17 | 2004-07-22 | Bunker Amy Mae | Amide and ester matrix metalloproteinase inhibitors |
| US20060247231A1 (en) * | 2003-12-18 | 2006-11-02 | Warner-Lambert Company Llc | Amide and ester matrix metalloproteinase inhibitors |
| TW200614993A (en) * | 2004-06-11 | 2006-05-16 | Akzo Nobel Nv | 4-phenyl-pyrimidine-2-carbonitrile derivatives |
| US20060173183A1 (en) * | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
| WO2006128184A2 (en) * | 2005-05-20 | 2006-11-30 | Alantos-Pharmaceuticals, Inc. | Pyrimidine or triazine fused bicyclic metalloprotease inhibitors |
| US20070155738A1 (en) | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
| JP2009522295A (ja) * | 2005-12-30 | 2009-06-11 | アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド | 置換ビス−アミドメタロプロテアーゼ阻害剤 |
| EP2049538A1 (en) * | 2006-05-30 | 2009-04-22 | NeuroSearch A/S | Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives and their medical use |
| CA2670044A1 (en) * | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic matrix metalloprotease inhibitors |
| JP2011529502A (ja) * | 2008-07-28 | 2011-12-08 | ポリメディックス・インコーポレーテッド | 抗マラリア化合物 |
| GB201908453D0 (en) | 2019-06-12 | 2019-07-24 | Enterprise Therapeutics Ltd | Compounds for treating respiratory disease |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3118754A (en) * | 1961-10-10 | 1964-01-21 | Pfizer & Co C | Process for stimulating plant growth |
| JPS5427350B2 (enExample) * | 1971-10-06 | 1979-09-10 | ||
| US4031104A (en) * | 1972-04-18 | 1977-06-21 | Bayer Aktiengesellschaft | 1,4-Dihydropyridine carboxylic acid esters |
| GR851819B (enExample) * | 1984-08-17 | 1985-11-26 | Wyeth John & Brother Ltd | |
| EP0260057A3 (en) * | 1986-09-02 | 1989-02-01 | The University Of Melbourne | 2-oxo-4-carboxy-pyrimidines |
| US5425289A (en) | 1993-10-21 | 1995-06-20 | Snap-On Incorporated | Bung tool |
| DE3931432A1 (de) * | 1989-09-21 | 1991-04-04 | Hoechst Ag | Pyrimidin-4,6-dicarbonsaeurediamide, verfahren zu deren herstellung sowie verwendung derselben sowie arzneimittel auf basis dieser verbindungen |
| DE4020570A1 (de) | 1990-06-28 | 1992-01-02 | Hoechst Ag | 2,4- und 2,5-substituierte pyridin-n-oxide, verfahren zu deren herstellung sowie deren verwendung |
| US5260323A (en) | 1990-06-28 | 1993-11-09 | Hoechst Aktiengesellschaft | 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and their use |
| EP0541042A1 (de) | 1991-11-05 | 1993-05-12 | Hoechst Aktiengesellschaft | Pyridin-2,4- und 2,5-dicarbonsäureamide und deren Derivate, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| US5516775A (en) * | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
| JPH08151380A (ja) * | 1994-11-29 | 1996-06-11 | Kyorin Pharmaceut Co Ltd | ビス（トリフルオロメチルピロロインドールカルボン酸エステル）誘導体及びその製造方法 |
| JPH09301958A (ja) * | 1996-05-09 | 1997-11-25 | Nippon Shoji Kk | 新規ピリミジン化合物及び抗ロタウイルス剤 |
| US6008243A (en) * | 1996-10-24 | 1999-12-28 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use |
| WO1998025597A2 (en) * | 1996-12-09 | 1998-06-18 | Warner-Lambert Company | Method for treating and preventing heart failure and ventricular dilatation |
| JPH11199512A (ja) | 1997-10-24 | 1999-07-27 | Pfizer Prod Inc | 変形性関節症および他のｍｍｐ媒介疾患の治療のためのｍｍｐ−１３選択的阻害剤の使用 |
| UA59453C2 (uk) | 1998-08-12 | 2003-09-15 | Пфайзер Продактс Інк. | Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ |
| PA8498701A1 (es) | 1999-08-12 | 2002-08-26 | Pfizer Prod Inc | Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas |
| US6934639B1 (en) | 2000-02-25 | 2005-08-23 | Wyeth | Methods for designing agents that interact with MMP-13 |
| EP1138680A1 (en) | 2000-03-29 | 2001-10-04 | Pfizer Products Inc. | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors |
| BR0114917A (pt) | 2000-10-26 | 2003-07-01 | Pfizer Prod Inc | Inibidores de pirimidina-2,4,6-triona metaloproteinase |
| CZ20031083A3 (cs) | 2000-10-26 | 2004-03-17 | Pfizer Products Inc. | 5-Spiropyrimidin-2, 4, 6-trionové inhibitory metaloproteinasy |
| DOP2002000332A (es) | 2001-02-14 | 2002-08-30 | Warner Lambert Co | Inhibidores de piridina de metaloproteinasas de la matriz |
| DOP2002000333A (es) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz |
| PA8539301A1 (es) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Inhibidores de la metaloproteinasa de la matriz |
| DOP2002000328A (es) | 2001-02-14 | 2003-08-30 | Warner Lambert Co | Pirimidinas inhibidoras de metaloproteinasas de matriz |
| US6924276B2 (en) * | 2001-09-10 | 2005-08-02 | Warner-Lambert Company | Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors |
| CA2462442A1 (en) * | 2001-10-12 | 2003-04-24 | Warner-Lambert Company Llc | Alkyne matrix metalloproteinase inhibitors |
| DE10160357A1 (de) | 2001-12-08 | 2003-06-18 | Aventis Pharma Gmbh | Verwendung von Pyridin-2,4-dicarbonsäurediamiden und Pyrimidin-4,6-dicarbonsäurediamiden zur selektiven Inhibierung von Kollagenasen |
| US6933298B2 (en) * | 2001-12-08 | 2005-08-23 | Aventis Pharma Deutschland Gmbh | Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases |
| US7166609B2 (en) * | 2002-11-02 | 2007-01-23 | Sanofi-Aventis Deutschland Gmbh | Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases |
| US20050004111A1 (en) * | 2003-01-03 | 2005-01-06 | Aventis Pharma Deutschland Gmbh | Selective MMP-13 inhibitors |
-
2002
- 2002-01-18 DO DO2002000328A patent/DOP2002000328A/es unknown
- 2002-01-18 WO PCT/IB2002/000190 patent/WO2002064571A1/en not_active Ceased
- 2002-01-18 AT AT02740096T patent/ATE472535T1/de not_active IP Right Cessation
- 2002-01-18 CA CA002433772A patent/CA2433772C/en not_active Expired - Fee Related
- 2002-01-18 DE DE60236851T patent/DE60236851D1/de not_active Expired - Lifetime
- 2002-01-18 BR BR0207209-2A patent/BR0207209A/pt not_active IP Right Cessation
- 2002-01-18 JP JP2002564504A patent/JP2004518723A/ja active Pending
- 2002-01-18 EP EP02740096A patent/EP1368323B1/en not_active Expired - Lifetime
- 2002-01-18 MX MXPA03004920A patent/MXPA03004920A/es active IP Right Grant
- 2002-01-25 GT GT200200010A patent/GT200200010A/es unknown
- 2002-02-05 PA PA20028538401A patent/PA8538401A1/es unknown
- 2002-02-08 UY UY27154A patent/UY27154A1/es not_active Application Discontinuation
- 2002-02-13 TN TNTNSN02010A patent/TNSN02010A1/fr unknown
- 2002-02-13 US US10/075,909 patent/US6936616B2/en not_active Expired - Fee Related
- 2002-02-13 PE PE2002000120A patent/PE20020874A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004518723A5 (enExample) | ||
| JP2004517087A5 (enExample) | ||
| RU2332212C2 (ru) | Аминоспирт | |
| MXPA05005379A (es) | Tioureas de arilo sustituidas y compuestos relacionados; inhibidores de duplicacion viral. | |
| JP2006506443A5 (enExample) | ||
| EP2251327A3 (en) | Heterocyclic inhibitors of MEK and methods of use thereof | |
| MA27390A1 (fr) | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique | |
| JPH11193282A5 (enExample) | ||
| CA2410662A1 (en) | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus | |
| JP2007515405A5 (enExample) | ||
| CA2503868A1 (en) | Sulfonamides, sulfamates and sulfamides as gamma-secretase inhibitors | |
| JP2007535491A5 (enExample) | ||
| IN2015DN01132A (enExample) | ||
| RU2013119129A (ru) | Органические соединения | |
| TW200600492A (en) | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | |
| JP2000086657A5 (enExample) | ||
| RU2367650C2 (ru) | Циклоалкендикарбоновые кислоты как противовоспалительные, иммуномодулирующие и антипролиферативные средства | |
| TW200738698A (en) | Organic compounds | |
| EA200500095A1 (ru) | Производные 4-(7-гало-2-хино(кса-)линилокси)феноксипропионовой кислоты в качестве противоопухолевых средств | |
| CA2440014A1 (en) | Beta-carboline derivatives and its pharmaceutical use against depression and anxiety | |
| JP2005502636A5 (enExample) | ||
| JP2005511535A5 (enExample) | ||
| CA2589744A1 (en) | Pyrrolinidium derivatives as m3 muscarinic receptors | |
| CA2441309A1 (en) | Biguanide derivatives | |
| JP2007507472A5 (enExample) |